Advances in Identifying Urine/Serum Biomarkers in Alpha-1 Antitrypsin Deficiency for More Personalized Future Treatment Strategies

References

• Blanco I, deSerres FJ, Fernandez-Bustillo E, Lara B, Miravitles M. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J 2006; 27(1):77–84.
   PubMed Web of Science ®Google Scholar
• de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: Summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122(5):1818–1829.
   PubMed Web of Science ®Google Scholar
• Lieberman J, Winter B. Alpha1-antitrypsin Pi-Types in 965 COPD patients. Chest 1986; 89(3):370–373.
   PubMed Web of Science ®Google Scholar
• Molina J, Flor X, García R, Timiraos R, Tirado-Conde G, Miravitlles M. The IDDEA project: A strategy for the detection of alpha-1 antitrypsin deficiency in COPD patients in the primary care setting. Ther Adv Respir Dis 2011; 5(4):237–243.
   PubMedGoogle Scholar
• O'Brien ME, Pennycooke K, Carroll TP, Shum J, Fee LT, O'Connor C, et al. The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease. COPD 2015; 12(S1):2–9.
   PubMedGoogle Scholar
• Strange C. Airways disease in alpha-1 antitrypsin deficiency. COPD 2013; 10(S1):68–73.
   PubMedGoogle Scholar
• McElvaney NG, Stoller JK, Buist AS, Prakash UB, Brantly ML, Schluchter MD, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111(2):394–403.
   Google Scholar
• Silverman EK, Sandhaus RA. Alpha1-antitrypsin deficiency. New Engl J Med 2009; 360(26):2749–2757.
   PubMed Web of Science ®Google Scholar
• Lomas DA, Parfrey H. Alpha1-antitrypsin: molecular pathophysiology. Thorax 2004; 59(6):529–535.
   PubMed Web of Science ®Google Scholar
• Lynch JP, Saggar R, Weigt SS, Ross DJ, Belperio JA. Overview of lung transplantation and criteria for selection of candidates. Semin Respir Crit Care Med 2006; 27(5):441–469.
   PubMed Web of Science ®Google Scholar
• Ottaviani S, Gorrini M, Scabini R, Kadija Z, Paracchini E, Mariani F, et al. C reactive protein and alpha 1-antitrypsin: relationship between levels and gene variants. Transl Res 2011; 157(6):332–338.
   PubMed Web of Science ®Google Scholar
• Ferrarotti I, Scabini R, Campo I, Ottaviani S, Zorzetto M, Gorrini M, et al. Laboratory diagnosis of Alpha1-antitrypsin deficiency. Transl Res 2007; 150(5):267–274.
   PubMed Web of Science ®Google Scholar
• Ferrarotti I, Thun GA, Zorzetto M, Ottaviani S, Imboden M, Schindler C, et al. Serum levels and genotype distribution of α1-antitrypsin in the general population. Thorax 2012; 67(8):669–674.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Lung Disease revised 2011, www.goldcopd.com.
   Google Scholar
• Madani A, Keyzer C, Gevenois PA. Quantitative computed tomography assessment of lung structure and function in pulmonary emphysema. Eur Respir J 2001; 18(4):720–730.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/European Respiratory Society statement. standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168(7):818–900.
   PubMed Web of Science ®Google Scholar
• Isada CM, Stoller JK. Chronic bronchitis: the role of antibiotics. In: Niederman MS, Sarosi GA, Glassroth J, eds. Respiratory infections: a scientific basis for management London: WB Saunders, 1994:621–633.
   Google Scholar
• Siafakas NM, Celli BR. Overall management of stable chronic obstructive Pulmonary disease. In: Siafakas NM, ed. Management of chronic obstructive pulmonary disease. Eur Respir Mon 2006; 38:258–265.
   Google Scholar
• Sandhaus RA, Turino G, Brantly ML, Cross CE, Campos M, Goodman K, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis (Miami) 2016; 3(3):668–682.
   PubMed Web of Science ®Google Scholar
• Stockley RA, Miravitlles M, Vogelmeier C. Alpha One International Registry (A.I.R.). Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalized approach. Orphanet J Rare Dis 2013; 8:149.
   PubMed Web of Science ®Google Scholar
• Franciosi AN, McCarthy C, McElvaney NG. The efficacy and safety of inhaled human α−1 antitrypsin in people with α−1 antitrypsin deficiency-related emphysema. Expert Rev Respir Med 2015; 9(2):143–151.
   PubMed Web of Science ®Google Scholar
• Vijayasaratha K, Stockley RA. Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD. Int J Chron Obstruct Pulmon Dis 2012; 7:789–796.
   PubMed Web of Science ®Google Scholar
• Stolk J, Stockley RA, Piitulainen E, Stoel BC. Relationship between change in lung density and long-term progression of lung function. Am J Respir Crit Care Med 2015; 192(1):114–116.
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31:416–469.
   PubMed Web of Science ®Google Scholar
• Macintyre N, Crapo RO, Viegi G, Johnson DC, Van Der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26:720–735.
   PubMed Web of Science ®Google Scholar
• Parr DG, Dirksen A, Piitulainen E, Deng C, Wencker M, Stockley RA. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency. Respir Res 2009; 10:75.
   PubMed Web of Science ®Google Scholar
• Marsh S, Aldington S, Williams MV, Nowitz MR, Kingzett-Taylor A, Weatherall M, et al. Utility of lung density measurements in the diagnosis of emphysema. Respir Med 2007; 101:1512–1520.
   PubMed Web of Science ®Google Scholar
• Ma S, Lieberman S, Turino GM, Lin YY. The detection and quantification of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum. Proc Natl Acad Sci USA 2003; 100(22):12941–12943.
   PubMed Web of Science ®Google Scholar
• Zanaboni G, Grimm R, Dyne KM, Rossi A, Cetta G, Iadarola P. Use of capillary zone electrophoresis for analysis of imidodipeptides in urine of prolidase-deficient patients. J Chromatogr B Biomed Appl 1996; 683(1):97–107.
   PubMed Web of Science ®Google Scholar
• Gottlieb DJ, Stone PJ, Sparrow D, Gale ME, Wales ST, Snider GL, et al. Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. Am J Respir Crit Care Med 1996; 154(5):1290–1295.
   PubMed Web of Science ®Google Scholar
• Bode DC, Pagani ED, Cumiskey WR, Von Roemeling R, Hamel L, Silver PJ. Comparison of urinary desmosine excretion in patients with chronic obstructive pulmonary disease or cystic fibrosis. Pulm Pharmacol Ther 2000; 13(4):175–180.
   PubMed Web of Science ®Google Scholar
• McClintock DE, Starcher B, Eisner MD, Thompson BT, Hayden DL, Church GD, et al. Higher urine desmosine levels are associated with mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2006; 291(4):L566–L571.
   Google Scholar
• Stone PJ, Konstan MW, Berger M, Dorkin HL, Franzblau C, Snider GL. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med 1995; 152(1):157–162.
   PubMed Web of Science ®Google Scholar
• Perła-Kajan J, Gryszczyn´ska A, Mielcarek S, Jakubowski H. Cation exchange HPLC analysis of desmosines in elastin hydrolysates. Anal Bioanal Chem 2011; 401(8):2473–2479.
   PubMed Web of Science ®Google Scholar
• Viglio S, Zanaboni G, Luisetti M, Trisolini R, Grimm R, Cetta G, et al. Micellar electrokinetic chromatography for the determination of urinary desmosine and isodesmosine in patients affected by chronic obstructive pulmonary disease. J Chromatogr B Biomed Sci Appl 1998; 714(1):87–98.
   PubMed Web of Science ®Google Scholar
• Annovazzi L, Viglio S, Perani E, Luisetti M, Baraniuk J, Casado B, et al. Capillary electrophoresis with laser-induced fluorescence detection as a novel sensitive approach for the analysis of desmosines in real samples. Electrophoresis 2004; 25(4–5):683–691.
   PubMed Web of Science ®Google Scholar
• Viglio S, Annovazzi L, Luisetti M, Stolk J, Casado B, Iadarola P. Progress in the methodological strategies for the detection in real samples of desmosine and isodesmosine, two biological markers of elastin degradation. J Sep Sci 2007; 30(2):202–213.
   PubMed Web of Science ®Google Scholar
• Annovazzi L, Viglio S, Gheduzzi D Pasquali-Ronchetti I, Zanone C, Cetta G, et al. High levels of desmosines in urine and plasma of patients with pseudoxanthoma elasticum. Eur J Clin Invest 2004; 34(2):156–164.
   PubMed Web of Science ®Google Scholar
• Luisetti M, Ma S, Iadarola P, Stone PJ, Viglio S, Casado B, et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 2008; 32(5):1146–1157.
   PubMed Web of Science ®Google Scholar
• Ma S, Lin YY, Turino GM. Measurements of desmosine and isodesmosine by mass spectrometry in COPD. Chest 2007; 131(5):1363–1371.
   PubMed Web of Science ®Google Scholar
• Ma S, Turino GM, Lin YY. Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LC-MS/MS as biomarkers for elastin degradation. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879(21):1893–1898.
   PubMed Web of Science ®Google Scholar
• Boutin M, Ahmad I, Jauhiainen M, Lachapelle N, Rondeau C, Roy J, et al. NanoLC-MS/MS analyses of urinary desmosine, hydroxylysylpyridinoline and lysylpyridinoline as biomarkers for chronic graft-versus-host disease. Anal Chem 2009; 81(22):9454–9461.
   PubMed Web of Science ®Google Scholar
• Boutin M, Berthelette C, Gervais FG, Scholand MB, Hoidal J, Leppert MF, et al. High-sensitivity nanoLC-MS/MS analysis of urinary desmosine and isodesmosine. Anal Chem 2009; 81(5):1881–1887.
   PubMed Web of Science ®Google Scholar
• Devenport NA, Reynolds JC, Parkash V, Cook J, Weston DJ, Creaser CS, et al. Determination of free desmosine and isodesmosine as urinary biomarkers of lung disorder using ultra performance liquid chromatography-ion mobility-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:3797–801.
   PubMed Web of Science ®Google Scholar
• Shiraishi K, Matsuzaki K, Matsumoto A, Hashimoto Y, Iba K. Development of a robust LC-MS/MS method for determination of desmosine and isodesmosine in human urine. J Oleo Sci 2010; 59(8):431–439.
   PubMed Web of Science ®Google Scholar
• Lindberg CA, Engström G, de Verdier MG, Nihlén U, Anderson M, Forsman-Semb K, et al. Total desmosines in plasma and urine correlate with lung function. Eur Respir J 2012; 39(4):839–845.
   PubMed Web of Science ®Google Scholar
• Albarbarawi O, Barton A, Lin Z, Takahashi E, Buddharaju A, Brady J, et al. Measurement of urinary total desmosine and isodesmosine using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal Chem 2010; 82(9):3745–3750.
   PubMed Web of Science ®Google Scholar
• Albarbarawi O, Barton A, Miller D, McSharry C, Chaudhuri R, Thomson NC, et al. Characterization and validation of an isotope-dilution LC-MS/MS method for quantification of total desmosine and isodesmosine in plasma and serum. Bioanalysis 2013; 5(16):1991–2001.
   PubMed Web of Science ®Google Scholar
• Huang JT, Chaudhuri R, Albarbarawi O, Barton A, Grierson C, Rauchhaus P, et al. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax 2012; 67(6):502–508.
   PubMed Web of Science ®Google Scholar
• Ongay S, Hendriks G, Hermans J, van den Berge M, ten Hacken NH, van de Merbel NC, et al. Quantification of free and total desmosine and isodesmosine in human urine by liquid chromatography tandem mass spectrometry: a comparison of the surrogate-analyte and the surrogate-matrix approach for quantitation. J Chromatogr A 2014; 1326:13–19.
   PubMed Web of Science ®Google Scholar
• Cohen AB, Girard W, McLarty J, Starcher B, Davis D, Stevens M, et al. A controlled trial of colchicine to reduce the elastase load in the lungs of ex-cigarette smokers with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143(5 Pt 1):1038–1043.
   PubMed Web of Science ®Google Scholar
• Gottlieb DJ, Luisetti M, Stone PJ, Allegra L, Cantey-Kiser JM, Grassi C, et al. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group. Am J Respir Crit Care Med 2000; 162(6):2069–2072.
   PubMed Web of Science ®Google Scholar
• Stoller JK, Rouhani F, Brantly M, Shanin S, Dweik RA, Stocks JM, et al. Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. Chest 2002; 122(1):66–74.
   PubMed Web of Science ®Google Scholar
• Agusti A, Sin DD. Biomarkers in COPD. Clin Chest Med 2014; 35(1):131–141.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Silverman EK, Thing B, Campbell EJ. Plasma levels of elastase-specific fibrinopeptides correlate with proteinase inhibitor phenotype. Evidence for increased elastase activity in subjects with homozygous and heterozygous deficiency of alpha 1-proteinase inhibitor. J Clin Invest 1992; 89(3):766–773.
   PubMed Web of Science ®Google Scholar
• Stolk J, Nieuwenhuizen W, Stoller JK, Aboussouan L. High dose intravenous AAT and plasma neutrophil derived fibrinogen fragments. Thorax 2005; 60(1):84.
   PubMed Web of Science ®Google Scholar
• Bos R, van Leuven CJ, Stolk J, Hiemstra PS, Ronday HK, Nieuwenhiuzen W. An enzyme immunoassay for polymorphonuclear leucocyte-mediated fibrinogenolysis. Eur J Clin Invest 1997; 27(2):148–156.
   PubMed Web of Science ®Google Scholar
• Bos R, van Leuven CJ, Stolk J, Hiemstra PS, Dijkman JH, Nieuwenhiuzen W. A monoclonal antibody with high affinity for a neo-antigenic site in fibrinogen degraded by polymorphonuclear leukocyte-derived elastase. Blood Coagul Fibrinolysis 1995; 6(3):259–267.
   PubMed Web of Science ®Google Scholar
• Stolk J, Veldhuisen B, Annovazzi L, Zanone C, Versteeq EM, van Kuppevelt TH, et al. Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency. Respir Res 2005; 6:47. Erratum in: Respir Res 2006; 7(1):20.
   Web of Science ®Google Scholar
• Carter RI, Ungurs MJ, Mumford RA, Stockley RA. Aα-Val360: a marker of neutrophil elastase and COPD disease activity. Eur Respir J 2013; 41(1):31–38.
   PubMed Web of Science ®Google Scholar
• Carter RI, Ungurs MI, Pillai A, Mumford RA, Stockley RA. The Relationship of the Fibrinogen Cleavage Biomarker Aα-Val360 with Disease Severity and Activity in Alpha-1-antitrypsin Deficiency. Chest 2015; 148(2):382–388.
   PubMed Web of Science ®Google Scholar
• Ito I, Nagai S, Handa T, Muro S, Hirai T, Tsukino M, et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005; 172(11):1378–1382.
   PubMed Web of Science ®Google Scholar
• Omachi TA, Eisner MD, Rames A Markovtsova L, Blanc PD. Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency. Respir Res 2011; 12:35.
   PubMed Web of Science ®Google Scholar
• Moreno JA, Ortega-Gomez A, Rubio-Navarro A, Louedec L, Ho-Tin-Noé B, Caligiuri G, et al. High-density lipoproteins potentiate α1-antitrypsin therapy in elastase-induced pulmonary emphysema. Am J Respir Cell Mol Biol 2014; 51(4):536–549.
   PubMed Web of Science ®Google Scholar
• Koepke J, Dresel M, Schmid S, Greulich T, Beutel B, Schmeck B, et al. Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO. PLoS One 2015; 10:e0117497.
   Google Scholar
• Lim JS, Yang JH, Chun BY, Kam S, Jacobs DR Jr, Lee DH. Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? Free Radic Biol Med 2004; 37(7):1018–1023.
   PubMed Web of Science ®Google Scholar
• Holme J, Dawkins PA, Stockley EK, Parr DG, Stocley RA. Studies of gamma-glutamyl transferase in alpha-1 antitrypsin deficiency. COPD 2010; 7(2):126–132.
   PubMedGoogle Scholar
• Pferdmenges DC, Baumann U, Müller-Heine A, Framke T, Pfister ED. Prognostic marker for liver disease due to alpha1-antitrypsin deficiency. Klin Padiatr 2013; 225(5):257–262.
   PubMed Web of Science ®Google Scholar
• Tanash HA, Nystedt-Düzakin M, Montero LC, Sveger T, Piitulainen E. The Swedish Alpha 1-antitrypsin Screening Study: Health Status, Lung and Liver Function at Age 34. Ann Am Thorac Soc 2015; 12(6):807–812.
   PubMed Web of Science ®Google Scholar
• Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, et al. Enhanced liver fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2010; 18(1):23–31.
   Web of Science ®Google Scholar
• Janciauskiene S, Wallmark A, Piitulainen E, Kohnlein T, Welte T, Sveger T. Performance of enhanced liver fibrosis plasma markers in asymptomatic individuals with ZZ α1-antitrypsin deficiency. Eur J Gastroenterol Hepatol 2011; 23(8):716–720.
   PubMed Web of Science ®Google Scholar
• Tan L, Dickens JA, DeMeo DL, Miranda E, Perez J, Rachid ST, et al. Circulating polymers in α 1-antitrypsin deficiency. Eur Respi J 2014; 43(5):1501–1504.
   PubMed Web of Science ®Google Scholar
• Fra A, Cosmi F, Ordonez A, Berardelli R, Perez J, Guadagno NA, et al. Pathological polymers of Z alpha1-AT can be secreted from cells through the canonical segretory pathway. Eur Respi J 2016; 47:1005–1009.
   PubMed Web of Science ®Google Scholar
• Mulgrew AT, Taggart CC, Lawless MW, Greene CM, Brantly ML, O'Neill SJ, et al. Z a1-antitrypsin polymerizes in the lung and acts as a neuthophil chemoattactant. Chest 2004; 125:1952–1957.
   PubMed Web of Science ®Google Scholar
• Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MM, et al. Long-term culture of genome-stable bi-potent stem cells from adult human liver. Cell 2015; 160(1–2):299–312.
   PubMed Web of Science ®Google Scholar
• Frenzel E, Wrenger S, Immenschuh S, Koczulla R, Mahadeva R, Deeg HJ, et al. Acute-phase protein α1-antitrypsin—a novel regulator of angiopoietin-like protein 4 transcription and secretion. J Immunol 2014; 192(11):5354–5362.
   PubMed Web of Science ®Google Scholar
• Leidinger P, Keller A, Borries A, Huwer H, Rohling M, Huebers J, et al. Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. Lung Cancer 2011; 74(1):41–47.
   PubMed Web of Science ®Google Scholar
• Wang M, Huang Y, Liang Z, Liu D, Liu Y, Lu Y, et al. Plasma miRNAs might be promising biomarkers of chronic obstructive pulmonary disease. Clin Respir J 2016; 10(1):104–111.
   PubMed Web of Science ®Google Scholar
• Hassan T, Carroll TP, Buckley PG, Cummins R, O'Neill SJ, McElvaney NG, et al. miR-199a-5p silencing regulates the unfolded protein response in chronic obstructive pulmonary disease and α1-antitrypsin deficiency. Am J Respir Crit Care Med 2014; 189(3):263–273.
   PubMed Web of Science ®Google Scholar
• Janciauskiene S, Welte T. Augmentation therapy with alpha1-antitrypsin: novel perspective. Cardiovasc Haematol Disord Drug Targets 2013; 13(2):90–98.
   PubMedGoogle Scholar
• Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, et al. Exploring the role of CT densitometry: A randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33(6):1345–1353.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, et al. Intravenous augmentation treatment and lung density in severe α 1 antitrypsin deficiency (RAPID): A randomized, double-blind, placebo-controlled trial. Lancet 2015; 386(9991):360–368.
   PubMed Web of Science ®Google Scholar
• Shapira MG, Khalfin B, Lewis EC, Parola AH, Nathan I. Regulation of autophagy by α1-antitrypsin: “A foe of a foe is a friend.” Mol Med 2014; 20:417–426.
   PubMed Web of Science ®Google Scholar